Reported resultsCompany-reported
What was reported
EDEN PRAIRIE, Minn. – October 5, 2026 – NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, today announced preliminary, unaudited product revenue for its fourth fiscal quarter and full fiscal year ended September 30, 2026, and provided an update on recent product orders.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Oct 5, 2026 · Open the source ↗
What the evidence supports
NeuroOne Medical published its results for the period in a press release furnished to the SEC (Form 8-K, Item 2.02).
What remains unknown
Audit status of the figures (results furnished on Form 8-K or 6-K are typically unaudited), and anything about future periods. Any outlook is the company's own projection. Figures and claims are the company's own description and have not been independently verified.
Figures as stated
Numbers exactly as written in the source. We don’t annualise, convert or add them up.
| Figure | In context |
|---|---|
| $3.8 million | “NeuroOne expects to report fourth quarter fiscal 2026 product revenue of approximately $3.8 million, representing year-over-year growth of 38.4%, compared to approximately $2.7 million in the fourth quarter of fiscal 2025.” Mentions: revenue |
| $2.7 million | “NeuroOne expects to report fourth quarter fiscal 2026 product revenue of approximately $3.8 million, representing year-over-year growth of 38.4%, compared to approximately $2.7 million in the fourth quarter of fiscal 2025.” Mentions: revenue |
| $10.5 million | “For the full fiscal year 2026, the Company expects to report revenue of approximately $10.5 million, representing 15.6% year-over-year growth and landing at the top of its previously announced revenue guidance range of $9.2 million to $10.5 million.” Mentions: revenue, guidance |
| $9.2 million | “For the full fiscal year 2026, the Company expects to report revenue of approximately $10.5 million, representing 15.6% year-over-year growth and landing at the top of its previously announced revenue guidance range of $9.2 million to $10.5 million.” Mentions: revenue, guidance |
| $4.5 million | “In September 2026, NeuroOne secured a $4.5 million product purchase order, the largest in the Company’s history.” Mentions: order |
| $1.0 million | “Approximately $1.0 million of the order shipped in September 2026, with shipments of the remaining $3.6 million expected to begin during the first quarter of fiscal 2027 and into the second quarter of fiscal 2027, subject to manufacturing and delivery schedules.” Mentions: order |
Source passages
Exact excerpts from the source, with links. Quotes are checked character for character against our stored copy.
Press release headlineNeuroOne Reports Preliminary Fiscal Q4 Product Revenue Growth of 38.4%; Secures Record $4.5 Million Purchase OrderU.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Oct 5, 2026 · Open the source ↗
Press release lead paragraphEDEN PRAIRIE, Minn. – October 5, 2026 – NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, today announced preliminary, unaudited product revenue for its fourth fiscal quarter and full fiscal year ended September 30, 2026, and provided an update on recent product orders.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Oct 5, 2026 · Open the source ↗
Amount stated in press releaseNeuroOne expects to report fourth quarter fiscal 2026 product revenue of approximately $3.8 million, representing year-over-year growth of 38.4%, compared to approximately $2.7 million in the fourth quarter of fiscal 2025.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Oct 5, 2026 · Open the source ↗
Amount stated in press releaseFor the full fiscal year 2026, the Company expects to report revenue of approximately $10.5 million, representing 15.6% year-over-year growth and landing at the top of its previously announced revenue guidance range of $9.2 million to $10.5 million.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Oct 5, 2026 · Open the source ↗
Amount stated in press releaseIn September 2026, NeuroOne secured a $4.5 million product purchase order, the largest in the Company’s history.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Oct 5, 2026 · Open the source ↗
Amount stated in press releaseApproximately $1.0 million of the order shipped in September 2026, with shipments of the remaining $3.6 million expected to begin during the first quarter of fiscal 2027 and into the second quarter of fiscal 2027, subject to manufacturing and delivery schedules.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Oct 5, 2026 · Open the source ↗
Revision history
- Revision 1 · Oct 28, 2026, 20:54 UTC
NeuroOne Reports Preliminary Fiscal Q4 Product Revenue Growth of 38.4%; Secures Record $4.5 Million Purchase Order
Spotted an error? Tell us. Corrections are published, never silent: see all corrections.